ストックスクリーナーアプリを入手
0.00
100.00%
-3.18
前日終値:
$3.18
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$819.46M
収益：
$418.24M
当期純損益:
$-7.42M
株価収益率:
0.00
EPS:
-0.1034
ネットキャッシュフロー:
$-10.88M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
名前
Esperion Therapeutics Inc
セクター
電話
734-887-3903
住所
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
0.00 | 819.46M | 418.24M | -7.42M | -10.88M | -0.1034 |
TAK
Takeda Pharmaceutical Co Adr
|
16.93 | 55.69B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.905 | 43.77B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.33 | 36.19B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.27 | 32.25B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
515.99 | 26.29B | 3.17B | 1.29B | 1.01B | 27.09 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-25 | 開始されました | Piper Sandler | Overweight |
| 2024-12-18 | 開始されました | Goldman | Neutral |
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-01 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | アップグレード | BofA Securities | Underperform → Buy |
| 2023-03-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-03-16 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | 再開されました | BofA Securities | Neutral |
| 2023-02-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-02-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-03-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-19 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | ダウングレード | Stifel | Buy → Hold |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-02-12 | ダウングレード | Jefferies | Buy → Hold |
| 2021-02-09 | ダウングレード | Goldman | Neutral → Sell |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-10 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Underweight |
| 2020-08-11 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | 再開されました | BofA/Merrill | Buy |
| 2020-03-17 | アップグレード | Citigroup | Neutral → Buy |
| 2020-02-24 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-09-16 | アップグレード | Goldman | Sell → Neutral |
| 2019-05-29 | ダウングレード | Goldman | Neutral → Sell |
| 2019-05-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | アップグレード | Goldman | Sell → Neutral |
| 2019-03-13 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-07 | 繰り返されました | Needham | Strong Buy |
| 2018-12-13 | 開始されました | Goldman | Sell |
| 2018-10-29 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2018-07-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-05-02 | ダウングレード | BofA/Merrill | Buy → Underperform |
すべてを表示
Esperion Therapeutics Inc (ESPR) 最新ニュース
Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Esperion Therapeutics Inc (ESPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ESPR|Esperion Therapeutics Inc|Price:3.180| - TradingKey
Esperion Therapeutics Inc (ESPR) Cash Flow - TradingKey
Esperion Therapeutics, Inc. Revenue Breakdown – LSX:A1W1SJ - TradingView
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Akin, an Elite Global Law Firm - akingump.com
Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings - Moomoo
[EFFECT] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Esperion Therapeutics, Inc. SEC Filing (Jul 16, 2026) - Stock Titan
PFE6265887 Bond Coupon Profile — Rate & Payments - TradingView
Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake - Stock Titan
BioPharma Credit, Affiliate Lend $400 Million to Archimed for Esperion Therapeutics Deal - Moomoo
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR - TradingView
REGBioPharma Credit PLCUPDATE ON ARCHIMED ESPERION ACQUISITION - TradingView
PFE6265887 Bond Risk Profile - TradingView
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P Global BMI Index - marketscreener.com
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P TMI Index - marketscreener.com
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
PFE6265887 Bond Profile — Key Metrics - TradingView
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) director exits equity as merger pays $3.16 plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs - Stock Titan
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger - Stock Titan
Esperion Therapeutics (ESPR) director exits holdings in $3.16-per-share cash and CVR merger - Stock Titan
Esperion Therapeutics (ESPR) CCO swaps 424,536 RSUs for $3.16 cash plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) CLO equity cashed out at $3.16 plus CVRs - Stock Titan
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO exits equity in cash-and-CVR merger payout - Stock Titan
An unknown funds, managed by ArchiMed SAS completed the acquisition of Esperion Therapeutics, Inc. from Wasatch Advisors LP, BlackRock, Inc. and others. - marketscreener.com
[POSASR] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Esperion Therapeutics, Inc. SEC Filing (Jul 13, 2026) - Stock Titan
Esperion Therapeutics, Inc. Announces Board Changes - marketscreener.com
Esperion Therapeutics Acquired by Essence Parent Inc.: Merger, NASDAQ Delisting, and Contingent Value Rights Details – Minichart - Minichart
Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing - Stock Titan
Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from NASDAQ Biotechnology Index - marketscreener.com
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger - TradingView
Esperion Therapeutics Inc (ESPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Esperion shareholders approve merger with Essence Parent Inc. - The Globe and Mail
Esperion Therapeutics Stockholders Approve Merger with Essence Parent Inc. – Key SEC 8-K Filing Details - Minichart
Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote - Stock Titan
Esperion Therapeutics stock leans on its cholesterol portfolio. - ad-hoc-news.de
Esperion Therapeutics (ESPR) AGM 2026 Summary - Quartr
Esperion Therapeutics Inc (ESPR) 財務データ
収益
当期純利益
現金流量
EPS
0.12%
1.98%
大文字化:
|
ボリューム (24 時間):